• Explore /
  • Poster
  • / The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors.

The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors.

Abstract Poster

Authors

null

Sebastian Ochsenreither

Charité Comprehensive Cancer Center, Berlin, Germany

Sebastian Ochsenreither , Ulrich Keilholz , Konrad Friedrich Klinghammer , Christina Dicke , Maxim Kebenko , Elena Garralda , Josep Tabernero , Ignacio Matos , Domenica Lorusso , Francesco Raspagliesi , Luca Gianni , Gianluca Del Conte , Beate Habel , Hans Baumeister , Riccardo Belli , Alfredo Zurlo , Walter M. Fiedler

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Antibodies

Clinical Trial Registration Number

NCT03360734

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS2596)

DOI

10.1200/JCO.2018.36.15_suppl.TPS2596

Abstract #

TPS2596

Poster Bd #

422a

Abstract Disclosures

Similar Posters

First Author: Hui Kong Gan

First Author: Emiliano Calvo

Poster

2019 ASCO Annual Meeting

Phase 1 with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors.

Phase 1 with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors.

First Author: Maria Pia Morelli

First Author: John Sarantopoulos